ProNAi Therapeutics Files Registration Statement for Proposed Initial Public Offering

VANCOUVER, June 12, 2015 /CNW/ - ProNAi Therapeutics, Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.  All shares of common stock to be sold in the offering will be offered by ProNAi. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ProNAi intends to list its common stock on the NASDAQ Global Market under the ticker symbol "DNAI."

Jefferies LLC and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering. BofA Merrill Lynch is also serving as ProNAi's strategic IPO advisor. Wedbush PacGrow and SunTrust Robinson Humphrey are acting as co-managers.

This offering will be made only by means of a prospectus.  A copy of the preliminary prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: [phone], email: [email protected]; or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, by telephone at [phone], or by email at [email protected].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

SOURCE ProNAi Therapeutics Inc.

James Smith, Vice President, Corporate Affairs, ProNAi Therapeutics, 604.558.6545, [email protected]